Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHKA | P35790 | 1/20 | 0.53 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.51 |
| ▸ | CYP21A2 | P08686 | 1/20 | 0.51 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 2/20 | 0.50 |
| ▸ | DRD3 | P35462 | 2/20 | 0.50 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | CASP4 | P49662 | 1/20 | 0.46 |
| ▸ | CASP5 | P51878 | 1/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.44 |
| ▸ | NCF1 | P14598 | 1/20 | 0.44 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26706256 | 0.95 | CHKA (0.52) | CHKACYP17A1CYP21A2CYP11B1DRD2 | |
| SCHEMBL1779036 | 0.83 | CCR2 (0.49) | CHKACYP17A1CYP21A2CYP11B1 | |
| SCHEMBL13648737 | 0.83 | DRD2 (0.59) | DRD2DRD3 | |
| SCHEMBL7787432 | 0.81 | ITGB3 (0.53) | CYP17A1CYP21A2CYP11B1DRD2DRD3 | |
| SCHEMBL29941581 | 0.80 | ADRB2 (0.62) | CHKACYP17A1CYP21A2CYP11B1DRD2 | |
| SCHEMBL22848094 | 0.79 | DRD2 (0.59) | DRD2DRD3 | |
| SCHEMBL22848104 | 0.78 | DRD2 (0.58) | DRD2DRD3 | |
| SCHEMBL7787450 | 0.77 | DRD2 (0.46) | CYP17A1CYP21A2CYP11B1DRD2DRD3 | |
| SCHEMBL22542091 | 0.77 | MAPT (0.51) | DRD2DRD3CASP1CASP4CASP5 | |
| SCHEMBL7791797 | 0.76 | DRD2 (0.45) | CYP17A1CYP21A2CYP11B1DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339874-A1 | PIPERAZINYL COMPOUNDS AND METHODS FOR TREATING NEMATODE INFECTIONS | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2023-10-26 | — | — | US | disclosed |
| US-20230339874-A1 | PIPERAZINYL COMPOUNDS AND METHODS FOR TREATING NEMATODE INFECTIONS | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2023-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339874-A1 | PIPERAZINYL COMPOUNDS AND METHODS FOR TREATING NEMATODE INFECTIONS | EPX, EGLN3, NISCH | CHKA 1061/4885CYP17A1 600/4885CYP21A2 721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.